Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Jun 23, 2021 7:50am
119 Views
Post# 33433093

New Board member

New Board member
Frank Holler 
“President & CEO at Ponderosa Capital Inc.
Venture capitalist with a background as a life science entrepreneur and investment banker. Having been closely involved in the creation and development of three of Canada's leading life science companies, I am deeply committed to utilizing my experience, expertise and network to help build world class technology companies.
 
Specialties: Corporate strategy and finance
Collaborations and partnering
Mergers and acquisitions.”
 
Well this new board member might be helpful to get a good partner with good terms for the company when they are ready to go down that route.
It would be ideal to let go some of current members which have not done much more than adding to costs.
For a small bio tech with limited resources this board is getting too populated, some members have had no meaningful contribution since their arrival.
 
<< Previous
Bullboard Posts
Next >>